Results 1 to 10 of about 96,342 (294)

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement [PDF]

Stem Cell Reviews and Reports, 2020
The expressive number of deaths and confirmed cases of SARS-CoV-2 call for an urgent demand of effective and available drugs for COVID-19 treatment. CD147, a receptor on host cells, is a novel route for SARS-CoV-2 invasion.
Henning Ulrich, Micheli M Pillat
exaly   +3 more sources

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

New England Journal of Medicine, 2020
Background Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.
Alexandre B Cavalcanti, Fernando Godinho Zampieri, Regis Goulart Rosa   +2 more
exaly   +2 more sources

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection

Circulation: Arrhythmia and Electrophysiology, 2020
Background: The novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus disease 2019 pandemic.
Moussa Saleh, James K Gabriels, David Chang   +2 more
exaly   +2 more sources

Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.

PLoS ONE, 2022
BackgroundDuring the initial phase of the COVID-19 pandemic, there was great enthusiasm for the use of azithromycin with or without hydroxychloroquine.ObjectivesWe analyzed azithromycin consumption in Croatia in 2020 and compared this to the period 2017 ...
Nikolina Bogdanić, Loris Močibob, Toni Vidović, Ana Soldo, Josip Begovać   +4 more
doaj   +2 more sources

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

International Journal of Antimicrobial Agents, 2020
Philippe Gautret, Jean Christophe Lagier, Philippe Parola   +2 more
exaly   +2 more sources

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

International Journal of Infectious Diseases, 2020
Samia Arshad, Paul E Kilgore, Zohra S Chaudhry   +2 more
exaly   +2 more sources

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin

Nature Medicine, 2020
Lalit Wadhwani, Chirag R Barbhaiya, Anthony Aizer,, Fhrs   +2 more
exaly   +2 more sources

Outcomes associated with azithromycin use among patients hospitalized with non-severe community-acquired pneumonia [PDF]

Antimicrobial Stewardship & Healthcare Epidemiology
Introduction: Community-acquired pneumonia (CAP) is the leading infectious cause for hospitalization. Guidelines recommend use of a macrolide antibiotic with a beta-lactam for coverage of atypical organisms; however, data supporting macrolide coverage ...
Ashwin Gupta, Emily Walzl, David Ratz, Jennifer Horowitz, Elizabeth McLaughlin, Tejal Gandhi, Lindsay Petty, Anurag Malani, David Paje, Preeti Misra, Scott Kaatz, Steven Bernstein, Mariam Younas, Scott Flanders, Valerie Vaughn   +14 more
doaj   +2 more sources

The use of Azithromycin and Hydroxychloroquine in the Treatment of Covid-19 [PDF]

SHS Web of Conferences, 2023
This paper mainly studies the therapeutic effect of azithromycin and hydroxychloroquine on COVID-19. Severe acute respiratory syndrome is one of the key clinical manifestations of COVID-19, and azithromycin is considered to be a feasible treatment.
Ma Yue, Lu Jiawei, Qin Si
doaj   +1 more source

Azithromycin and the microbiota of cystic fibrosis sputum

BMC Microbiology, 2021
Background Azithromycin is commonly prescribed drug for individuals with cystic fibrosis (CF), with demonstrated benefits in reducing lung function decline, exacerbation occurrence and improving nutrition.
Nicole Acosta, Christina S. Thornton, Michael G. Surette, Ranjani Somayaji, Laura Rossi, Harvey R. Rabin, Michael D. Parkins   +6 more
doaj   +1 more source